Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation

References

• Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7:1001 - 12; http://dx.doi.org/10.1038/nrd2637; PMID: 18989337
   PubMed Web of Science ®Google Scholar
• Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459 - 68; http://dx.doi.org/10.1200/JCO.2009.22.1291; PMID: 19826124
   PubMed Web of Science ®Google Scholar
• Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001; 130:265 - 72; http://dx.doi.org/10.1067/msy.2001.115897; PMID: 11490359
   PubMed Web of Science ®Google Scholar
• Inoue H, Shiraki K, Ohmori S, Sakai T, Deguchi M, Yamanaka T, et al. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med 2002; 9:521 - 5; PMID: 11956660
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101:4055 - 62; http://dx.doi.org/10.1182/blood-2002-11-3514; PMID: 12531799
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2:1273 - 84; PMID: 14707268
   PubMed Web of Science ®Google Scholar
• Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004; 314:186 - 91; http://dx.doi.org/10.1016/j.bbrc.2003.12.074; PMID: 14715264
   PubMed Web of Science ®Google Scholar
• Guo F, Sigua C, Tao J, Bali P, George P, Li Y, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64:2580 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-03-2629; PMID: 15059915
   PubMed Web of Science ®Google Scholar
• Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25:1813 - 20; http://dx.doi.org/10.1093/carcin/bgh188; PMID: 15142888
   PubMed Web of Science ®Google Scholar
• Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23:6261 - 71; http://dx.doi.org/10.1038/sj.onc.1207830; PMID: 15208660
   PubMed Web of Science ®Google Scholar
• Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors’ signaling and requires P21(waf1). Exp Cell Res 2004; 298:560 - 73; http://dx.doi.org/10.1016/j.yexcr.2004.04.038; PMID: 15265702
   PubMed Web of Science ®Google Scholar
• Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11:Suppl 2 S193 - 206; http://dx.doi.org/10.1038/sj.cdd.4401535; PMID: 15608694
   PubMed Web of Science ®Google Scholar
• Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005; 12:10 - 8; http://dx.doi.org/10.1038/sj.cdd.4401507; PMID: 15540114
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Gänge J, Kumar KS, Müller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 2005; 23:99 - 109; http://dx.doi.org/10.1007/s10637-005-5854-9; PMID: 15744585
   PubMed Web of Science ®Google Scholar
• Vanoosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11:542 - 52; http://dx.doi.org/10.1016/j.ymthe.2004.12.008; PMID: 15771957
   PubMed Web of Science ®Google Scholar
• Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB. Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther 2005; 4:382 - 90; http://dx.doi.org/10.4161/cbt.4.4.1615; PMID: 15846101
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12:773 - 82; http://dx.doi.org/10.1038/sj.cdd.4401649; PMID: 15861184
   PubMed Web of Science ®Google Scholar
• Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609 - 23; http://dx.doi.org/10.1038/sj.onc.1208585; PMID: 15897906
   PubMed Web of Science ®Google Scholar
• Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25:5404 - 16; http://dx.doi.org/10.1128/MCB.25.13.5404-5416.2005; PMID: 15964798
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005; 24:6877 - 89; http://dx.doi.org/10.1038/sj.onc.1208851; PMID: 16007142
   PubMed Web of Science ®Google Scholar
• Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7:646 - 57; http://dx.doi.org/10.1593/neo.04655; PMID: 16026644
   PubMed Web of Science ®Google Scholar
• VanOosten RL, Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4:1104 - 12; http://dx.doi.org/10.4161/cbt.4.10.2022; PMID: 16096370
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005; 11:3958 - 65; http://dx.doi.org/10.1158/1078-0432.CCR-03-0776; PMID: 15897598
   PubMed Web of Science ®Google Scholar
• El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 2006; 13:281 - 9; http://dx.doi.org/10.1038/sj.cgt.7700905; PMID: 16167063
   PubMed Web of Science ®Google Scholar
• Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005; 16:1125 - 38; PMID: 16273296
   PubMed Web of Science ®Google Scholar
• Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006; 15:227 - 30; PMID: 16328060
   PubMed Web of Science ®Google Scholar
• Earel JK Jr., VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006; 66:499 - 507; http://dx.doi.org/10.1158/0008-5472.CAN-05-3017; PMID: 16397266
   PubMed Web of Science ®Google Scholar
• Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer 2006; 119:221 - 8; http://dx.doi.org/10.1002/ijc.21824; PMID: 16450389
   PubMed Web of Science ®Google Scholar
• VanOosten RL, Earel JK Jr., Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006; 13:628 - 32; http://dx.doi.org/10.1038/sj.cgt.7700939; PMID: 16456549
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28:755 - 66; PMID: 16465382
   PubMed Web of Science ®Google Scholar
• Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai M, et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119:944 - 54; http://dx.doi.org/10.1002/ijc.21939; PMID: 16550602
   PubMed Web of Science ®Google Scholar
• Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006; 43:425 - 34; http://dx.doi.org/10.1002/hep.21054; PMID: 16583461
   PubMed Web of Science ®Google Scholar
• Thai M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, et al. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 2006; 66:5363 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-05-4386; PMID: 16707463
   PubMed Web of Science ®Google Scholar
• Inoue S, Twiddy D, Dyer MJ, Cohen GM. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 2006; 13:2160 - 2; http://dx.doi.org/10.1038/sj.cdd.4401977; PMID: 16729023
   PubMed Web of Science ®Google Scholar
• Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006; 66:6785 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-05-4563; PMID: 16818655
   PubMed Web of Science ®Google Scholar
• Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM, et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 2006; 8:446 - 57; http://dx.doi.org/10.1593/neo.05823; PMID: 16820090
   PubMed Web of Science ®Google Scholar
• Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006; 66:7317 - 25; http://dx.doi.org/10.1158/0008-5472.CAN-06-0680; PMID: 16849582
   PubMed Web of Science ®Google Scholar
• Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, et al. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. BMC Cancer 2006; 6:214; http://dx.doi.org/10.1186/1471-2407-6-214; PMID: 16930472
   PubMed Web of Science ®Google Scholar
• Fandy TE, Srivastava RK. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol 2006; 58:471 - 7; http://dx.doi.org/10.1007/s00280-005-0184-3; PMID: 16435155
   PubMed Web of Science ®Google Scholar
• Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006; 11:2251 - 65; http://dx.doi.org/10.1007/s10495-006-0283-6; PMID: 17051334
   PubMed Web of Science ®Google Scholar
• Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther 2007; 14:327 - 34; http://dx.doi.org/10.1038/sj.cgt.7701017; PMID: 17186014
   PubMed Web of Science ®Google Scholar
• Reddy RM, Yeow WS, Chua A, Nguyen DM, Baras A, Ziauddin MF, et al. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 2007; 12:55 - 71; http://dx.doi.org/10.1007/s10495-006-0484-z; PMID: 17136498
   PubMed Web of Science ®Google Scholar
• Garofalo M, Romano G, Quintavalle C, Romano MF, Chiurazzi F, Zanca C, et al. Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. Int J Cancer 2007; 120:1215 - 22; http://dx.doi.org/10.1002/ijc.22495; PMID: 17192900
   PubMed Web of Science ®Google Scholar
• VanOosten RL, Earel JK Jr., Griffith TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007; 12:561 - 71; http://dx.doi.org/10.1007/s10495-006-0009-9; PMID: 17195089
   PubMed Web of Science ®Google Scholar
• Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007; 9:440 - 51; http://dx.doi.org/10.1002/jgm.1036; PMID: 17410615
   PubMed Web of Science ®Google Scholar
• Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313:2378 - 88; http://dx.doi.org/10.1016/j.yexcr.2007.03.018; PMID: 17462628
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong TT, Klier U, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. J Cancer Res Clin Oncol 2007; 133:847 - 58; http://dx.doi.org/10.1007/s00432-007-0227-8; PMID: 17486365
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 2007; 67:6987 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-07-0812; PMID: 17638911
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, et al. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 2007; 35:1527 - 37; http://dx.doi.org/10.1016/j.exphem.2007.06.014; PMID: 17697742
   PubMed Web of Science ®Google Scholar
• Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008; 22:819 - 25; http://dx.doi.org/10.1038/leu.2008.1; PMID: 18239621
   PubMed Web of Science ®Google Scholar
• Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 2008; 57:233 - 46; http://dx.doi.org/10.1007/s00262-007-0370-8; PMID: 17665197
   PubMed Web of Science ®Google Scholar
• Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res 2008; 28:2A 855 - 64; PMID: 18507029
   PubMed Web of Science ®Google Scholar
• Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol Cancer Ther 2008; 7:1494 - 505; http://dx.doi.org/10.1158/1535-7163.MCT-08-0183; PMID: 18566220
   PubMed Web of Science ®Google Scholar
• Frew AJ, Lindemann RK, Martin BP, Clarke CJP, Sharkey J, Anthony DA, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008; 105:11317 - 22; http://dx.doi.org/10.1073/pnas.0801868105; PMID: 18685088
   PubMed Web of Science ®Google Scholar
• Dzieran J, Beck JF, Sonnemann J. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 2008; 99:1685 - 92; http://dx.doi.org/10.1111/j.1349-7006.2008.00868.x; PMID: 18754884
   PubMed Web of Science ®Google Scholar
• Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009; 93:303 - 18; http://dx.doi.org/10.1007/s11060-008-9788-x; PMID: 19148581
   PubMed Web of Science ®Google Scholar
• Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, Sharma S. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009; 4:149 - 60; http://dx.doi.org/10.1097/JTO.0b013e318194f991; PMID: 19179889
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, et al. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp Cell Res 2009; 315:1809 - 18; http://dx.doi.org/10.1016/j.yexcr.2009.02.024; PMID: 19268463
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol 2009; 77:1328 - 36; http://dx.doi.org/10.1016/j.bcp.2008.12.027; PMID: 19426671
   PubMed Web of Science ®Google Scholar
• Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009; 8:1596 - 605; http://dx.doi.org/10.1158/1535-7163.MCT-08-1004; PMID: 19509267
   PubMed Web of Science ®Google Scholar
• Norian LA, Kucaba TA, Earel JK, Knutson T, Vanoosten RL, Griffith TS. Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors. J Oncol 2009; 2009:408038; http://dx.doi.org/10.1155/2009/408038; PMID: 19547714
   PubMedGoogle Scholar
• Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009; 28:3097 - 110; http://dx.doi.org/10.1038/onc.2009.161; PMID: 19597472
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D’Anneo A, Emanuele S, Angileri L, Di Fazio P, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45:2425 - 38; http://dx.doi.org/10.1016/j.ejca.2009.06.024; PMID: 19643600
   PubMed Web of Science ®Google Scholar
• Yeh CC, Deng YT, Sha DY, Hsiao M, Kuo MY. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol Cancer Ther 2009; 8:2718 - 25; http://dx.doi.org/10.1158/1535-7163.MCT-09-0211; PMID: 19737941
   PubMed Web of Science ®Google Scholar
• Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 2010; 9:246 - 56; http://dx.doi.org/10.1158/1535-7163.MCT-09-0495; PMID: 20053768
   PubMed Web of Science ®Google Scholar
• Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009; 8:3088 - 97; http://dx.doi.org/10.1158/1535-7163.MCT-09-0451; PMID: 19887558
   PubMed Web of Science ®Google Scholar
• Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, Krammer PH, et al. Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer 2010; 127:1384 - 92; http://dx.doi.org/10.1002/ijc.25170; PMID: 20087862
   PubMed Web of Science ®Google Scholar
• D’Acunto CW, Carratù A, Rodriquez M, Taddei M, Parente L, Petrella A. LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis. Anticancer Res 2010; 30:887 - 94; PMID: 20393011
   PubMed Web of Science ®Google Scholar
• Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, et al. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 2010; 9:80; http://dx.doi.org/10.1186/1476-4598-9-80; PMID: 20398369
   PubMed Web of Science ®Google Scholar
• Kauh J, Fan S, Xia M, Yue P, Yang L, Khuri FR, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010; 5:e10376; http://dx.doi.org/10.1371/journal.pone.0010376; PMID: 20442774
   PubMed Web of Science ®Google Scholar
• Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5:e10941; http://dx.doi.org/10.1371/journal.pone.0010941; PMID: 20532179
   PubMed Web of Science ®Google Scholar
• Morales JC, Ruiz-Magaña MJ, Carranza D, Ortiz-Ferrón G, Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett 2010; 297:91 - 100; http://dx.doi.org/10.1016/j.canlet.2010.04.029; PMID: 20580868
   PubMed Web of Science ®Google Scholar
• Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010; 15:1256 - 69; http://dx.doi.org/10.1007/s10495-010-0521-9; PMID: 20582477
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010; 9:3254 - 66; http://dx.doi.org/10.1158/1535-7163.MCT-10-0582; PMID: 21041383
   PubMed Web of Science ®Google Scholar
• Martin BP, Frew AJ, Bots M, Fox S, Long F, Takeda K, et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int J Cancer 2011; 128:2735 - 47; http://dx.doi.org/10.1002/ijc.25594; PMID: 20715169
   PubMed Web of Science ®Google Scholar
• Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Res 2011; 71:1883 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-10-2252; PMID: 21363923
   PubMed Web of Science ®Google Scholar
• Kim DR, Park MY, Lee CS, Shim SH, Yoon HI, Lee JH, et al. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 2011; 18:467 - 77; http://dx.doi.org/10.1038/cgt.2011.11; PMID: 21455254
   PubMed Web of Science ®Google Scholar
• Yerbes R, López-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs 2010; In press http://dx.doi.org/10.1007/s10637-010-9597-x; PMID: 21107885
   PubMed Web of Science ®Google Scholar
• Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32:1450 - 8; http://dx.doi.org/10.1093/carcin/bgr135; PMID: 21771726
   PubMed Web of Science ®Google Scholar
• Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie 2011; In press PMID: 21835222
   PubMed Web of Science ®Google Scholar
• Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67:4981 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-4274; PMID: 17510429
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001; 61:2704 - 12; PMID: 11289151
   PubMed Web of Science ®Google Scholar
• Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther 2010; 9:1842 - 51; http://dx.doi.org/10.1158/1535-7163.MCT-09-0918; PMID: 20515944
   PubMed Web of Science ®Google Scholar
• Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008; 7:603 - 8; http://dx.doi.org/10.4161/cbt.7.4.5564; PMID: 18223318
   PubMed Web of Science ®Google Scholar
• Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM. Sensitivity of Ewing’s sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001; 8:506 - 14; http://dx.doi.org/10.1038/sj.cdd.4400836; PMID: 11423911
   PubMed Web of Science ®Google Scholar
• Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009; 459:428 - 32; http://dx.doi.org/10.1038/nature08012; PMID: 19363473
   PubMed Web of Science ®Google Scholar